Investors

At Alector, we are on a mission to slow the progression of neurodegenerative diseases and ultimately prevent their occurrence.

We are a clinical stage biopharmaceutical company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Our approach is based on insights into human genetics, immunology and neuroscience. Just as immuno-oncology therapies recruit the peripheral adaptive immune system to counteract tumors, our immuno-neurology therapies target immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders.

The result so far: an industry-leading portfolio of immuno-neurology programs designed to harness the brain’s immune system to fight disease that we are advancing through the clinic independently and with partners.

NASDAQ: ALEC

$20.99

+0.29 (+1.21%)

Data Provided by Refinitiv. Minimum 15 minutes delayed.

NASDAQ: ALEC

Price

$20.99

Change

+ 0.13 (+0.62%)

Volume

120,929

Previous Close

$20.86

Today's High

$21.82

Today's Low

$20.94

Data provided by Refinitiv. Minimum 15 minutes delayed.

Close